Detailed Program
Monday, 12 September | Tuesday, 13 September | Wednesday, 14 September | Thursday, 15 September
|
Monday, 12 September (back to top) |
| 16:00 – 17:10 |
Special Session |
Ballroom A, Level 22 |
||
| 16:00 – 16:10 |
Pratap Singhasivanon |
|||
|
16:10 – 16:20 |
José Esparza Global HIV Vaccine Enterprise Acting President of the Board Bill & Melinda Gates Foundation Seattle, WA, USA |
|||
|
16:20 – 16:40 |
Are There Lessons From Past Vaccines for an AIDS Vaccine? |
SS01.01 |
||
|
16:40 – 17:10 |
Moving Forward from RV144: An Industrial Perspective |
SS01.02 |
||
| 17:10 - 18:40 |
Poster Session 01 and Welcome Reception |
Ballroom B, Level 22 |
||
|
All posters ending in odd numbers were presented in Poster Session 01. |
||||
|
Tuesday, 13 September (back to top) |
| 08:30 – 10:00 |
Opening Ceremony |
Ballroom A, Level 22 |
||
| 8:30 - 08:45 |
Doors Opened. Entertainment Provided by Mahidol University Orchestra |
|||
| 09:00 – 09:20 |
Her Royal Highness |
|
||
|
09:20 – 09:50 |
Progress Towards an HIV Vaccine – Lessons Learned from HIV Prevention Carl Dieffenbach Division of AIDS, NIAID, NIH Bethesda, MD, USA |
OC01.01 |
||
| 10:00 – 10:30 |
Tea and Coffee Break |
Ballroom B, Level 22 |
||
| 10:30 – 12:30 |
Plenary Session 01: |
Ballroom A, Level 22 |
||
| 10:30 – 10:45 |
Africa's Contribution to AIDS Vaccine Research and Development |
PL01.01 |
||
|
10:45 – 11:00 |
Thailand's Contribution to HIV Vaccine Research and Development |
PL01.02 |
||
|
11:00 – 11:30 |
Update on RV144: Correlates, Sieve Analysis, and Clinical Development |
PL01.03 |
||
|
11:30 – 12:00 |
Case Control Study of the RV144 Trial for Immune Correlates: The Analysis and Way Forward |
PL01.04 |
||
|
12:00 – 12:30 |
Vaccines Beyond RV144 Poxvirus Vector-Based HIV Slides Unavailable |
PL01.05 |
||
| 12:30 – 13:30 |
Lunch Break |
Ballroom B, Level 22 |
||
| 13:30 – 15:00 |
Oral Abstract Session 01: |
Ballroom A, Level 22 |
||
| 13:30 - 13:45 |
DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell Responses in Intestinal Mucosa |
OA01.01 |
||
|
13:45 - 14:00 |
Cell-Mediated Immune Responses After DNA Delivered by Either Biojector or Electroporation and Boosted with a Heterologous Insert Recombinant Poxvirus |
OA01.02 |
||
|
14:00 - 14:15 |
Titered Mucosal Challenge of Rhesus Macaques with SIVmac251 Recapitulates HIV Vaccine Efficacy in Humans Slides Unavailable |
OA01.03 |
||
|
14:15 - 14:30 |
Preservation of HIV-1-Specific CD4+ T-IFNγ-Cell Responses in Intercurrent Infections Following Exposure to Tenofovir Gel Slides Unavailable |
OA01.04 |
||
|
14:30 - 14:45 |
Homologous Priming and Boosting with Recombinant MVA, Prevention of Infection as Good as With the Heterologous Regimen of DNA Priming and MVA Boosting Slides Unavailable |
OA01.05 |
||
|
14:45 - 15:00 |
Extended Evaluation of Volunteers Who Become HIV-1 Infected During Participation in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX® B/E |
OA01.06 LB |
||
| 13:30 – 15:00 |
Oral Abstract Session 02: |
Lotus 1-4, Level 22 |
||
| 13:30 - 13:45 |
Innate Immune Response Signatures to Ad5 (HVTN 071) and MVA (HVTN 205/908) Vectored Candidate HIV Vaccines Predict Induction of Adaptive Responses Slides Unavailable |
OA02.01 |
||
|
13:45 - 14:00 |
Frequent and Strong NK Responses to HIV-1 Env Peptides in Individuals with Acute and Chronic HIV-1 Infection Slides Unavailable CF Thobakgale, L. Fadda, K. Lane, F. Pereyra, B.D. Walker, T. Allen, M. Altfeld |
OA02.02 |
||
|
14:00 - 14:15 |
NKp46 and NKG2D Receptors Are Implicated in the Priming and Suppression of HIV Replication by Natural Killer Cells Stimulated by MVA/HIV ANRS Vaccine Slides Unavailable |
OA02.03 |
||
|
14:15 - 14:30 |
HIV Infection Eliminates the Antibody-Dependent Cellular Cytotoxicity (ADCC) Functional Advantage of KIR3DL1-Expressing NK Cells from HLA-Bw4 Carriers Slides Unavailable |
OA02.04 |
||
|
14:30 - 14:45 |
Inhibition of Human Immunodeficiency Virus Type 1 Infection of Human Monocyte-Derived Macrophages by Anti-Lipid and Anti-MPER Monoclonal Antibodies Slides Unavailable |
OA02.05 |
||
|
14:45 - 15:00 |
JAK3 Inhibition In Vivo in Chronically SIV Infected Rhesus Macaques Deplete NK-17 Cells |
OA02.06 LB |
||
| 13:30 – 15:00 |
Oral Abstract Session 03: |
Lotus 5-7, Level 22 |
||
| 13:30 - 13:45 |
Targeting Antigen to CD40 on Dendritic Cells Mediates Expansion of Multi-Epitope HIV-Specific Polyfunctional CD4+ and CD8+ T Cells Slides Unavailable |
OA03.01 |
||
|
13:45 - 14:00 |
Identification of Escape-Refractory Subdominant CD8 Epitopes for Common HLA Alleles |
OA03.02 |
||
|
14:00 - 14:15 |
HIV-1 gp120 V1V2-Scaffolds for Structural Analysis and Immunogen Design |
OA03.03 |
||
|
14:15 - 14:30 |
Identification of Mimotopes for Neutralizing Antibodies from Elite Controllers with Env-Tailored Phage Display Libraries Slides Unavailable |
OA03.04 |
||
|
14:30 - 14:45 |
Role of Hypervariable Loops in Intersubunit Associations of Env: Trimeric gp140 Immunogen as a Platform for Novel Epitope Display Slides Unavailable |
OA03.05 LB |
||
|
14:45 - 15:00 |
Development and Characterization of HIV-1 Virus-like Particles Produced by Stably Transfected Drosophila S2 cells Slides Unavailable |
OA03.06 |
||
|
15:00 – 15:30 |
Tea and Coffee Break |
Ballroom B, Level 22 |
||
| 15:30 – 17:15 |
Oral Abstract Session 04: |
Ballroom A, Level 22 |
||
| 15:30 - 15:45 |
Potent and Broad Neutralization by a CD4 Binding Site Monoclonal Antibody from an HIV-1 Infected Donor Slides Unavailable |
OA04.01 |
||
|
15:45 - 16:00 |
Human Anti-V2 Monoclonal Antibodies Neutralize Tier 1 HIV-1 Pseudoviruses Slides Unavailable |
OA04.02 |
||
|
16:00 - 16:15 |
2F5-like Cross-Reactive HIV-1-Neutralizing Monoclonal Antibodies with Low Number of Somatic Mutations |
OA04.03 |
||
|
16:15 - 16:30 |
Characterization of CD4-Binding Site Directed Monoclonal Antibodies Isolated from HIV-1 gp140 Env Immunized Rhesus Macaques |
OA04.04 |
||
|
16:30 - 16:45 |
Structural Insights into HIV-1 Neutralization by New Highly Potent and Broadly Neutralizing Antibodies Slides Unavailable |
OA04.05 |
||
|
16:45 – 17:00 |
AAV2/8-Encoded Vaccine Expressing a Broadly Neutralizing HIV Antibody Protects Humanized Mice from High-Dose Intravenous Viral Challenge Slides Unavailable L Yang, D Baltimore |
OA04.06 |
||
|
17:00 – 17:15 |
Evolution of HIV-1 Transmitted/Founder Viruses Results in the Formation of Epitopes for Later Broadly Rross-Neutralizing Antibodies |
OA04.07 LB |
||
| 15:30 – 17:00 |
Oral Abstract Session 05: |
Lotus 1 – 4, Level 22 |
||
| 15:30 - 15:45 |
HIV-Specific Cytolytic CD4+ T-Cell Responses During Acute HIV-1 Infection Predict Disease Outcome Slides Unavailable |
OA05.01 |
||
|
15:45 - 16:00 |
Control of Acute HIV-1 Subtype C Viremia Is Associated with Limited CD8+ T-Cell Immunogenicity Slides Unavailable |
OA05.02 |
||
|
16:00 - 16:15 |
Lymphocyte Dynamics in Acute HIV-1 Infection: RV217-The Early Capture HIV Cohort Study (ECHO) Slides Unavailable |
OA05.03 |
||
|
16:15 - 16:30 |
Long-Lived Historical Record of Evolution of Viral Diversity in Peripheral Blood Cells by Deep Pyrosequencing Slides Unavailable |
OA05.04 |
||
|
16:30 - 16:45 |
Dynamics of HIV-1 Subtype C Gag in the Global Epidemic |
OA05.05 |
||
|
16:45 - 17:00 |
Important Contribution of Subdominant HIV-Specific CD8 T Cell Responses to Early Control of HIV Replication |
OA05.06 |
||
| 15:30 – 17:00 |
Oral Abstract Session 06: |
Lotus 5 - 7, Level 22 |
||
| 15:30 - 15:45 |
Deconstructing HIV-Specific CD8+T Cell Responses in HIV Elite Controllers Slides Unavailable ZM Ndhlovu, LB Chibnik, J Proundfoot, S Vine, F Porichis, A McMullen, K Cesa, A Piechocka-Trocha, PL De Jager, DE Kaufmann, BD Walker |
OA06.01 |
||
|
15:45 - 16:00 |
Ontogeny of CD8+ T Cells in Acute HIV-1 that Inhibit Autologous and Heterologous Transmitted/Founder (T/F) Viruses Slides Unavailable |
OA06.02 |
||
|
16:00 - 16:15 |
The RV144 Vaccine Induced CD4+ T Cells Producing Th1 and Th2 Cytokines with Proliferative Potential |
OA06.03 |
||
|
16:15 - 16:30 |
Association of Timing of HLA B*8101 and B*3910 Mediated p24 Sequence Evolution and Pathways to CTL Escape with Disease Progression |
OA06.04 |
||
|
16:30 - 16:45 |
Evidence of HIV-Specific ADCC Immune Escape |
OA06.05 |
||
|
16:45 - 17:00 |
Imbalance Between T Helper Type 17 and T Regulatory Cells: Implications for HIV Pathogenesis Slides Unavailable |
OA06.06 |
||
|
17:15 – 21:30 |
Banquet at the Royal Navy Hall |
Wat Arun, Bangkok Yai |
||
|
Wednesday, 14 September (back to top) |
| 08:30 – 10:00 |
Plenary Session 02: |
Ballroom A, Level 22 |
||
| 08:30 – 09:00 |
Voluntary Medical Male Circumcision for HIV Prevention: What Are the Lessons for Other Prevention Strategies?
|
PL02.01 |
||
|
09:00 – 09:30 |
Lessons Learnt from HIV Pre- And Post-Infection Studies: Implications for Combination Prevention Strategies
|
PL02.02 |
||
|
09:30 – 10:00 |
What's New in Preventing Mother-to-Child HIV-1 Transmission (MTCT)
|
PL02.03 |
||
|
10:00 – 10:30 |
Tea and Coffee Break |
Ballroom B, Level 22 |
||
| 10:30 – 12:30 |
Symposia 01: |
Ballroom A, Level 22 |
||
| 10:30 – 10:54 |
Combination Prevention Where Clinical Trials and Public Health Are at Crossroads A. Cornelius Baker |
S01.01 |
||
|
10:54 – 11:18 |
Changing Standards of Care in South Africa: Considerations for HIV Vaccine Trials Glenda Gray |
S01.02 |
||
|
11:18 – 11:42 |
Community Engagement for Care in HIV Vaccine Trials: An Exploration of Ethical Considerations and Stakeholder Practices/Perspectives Slides Unavailable Catherine Slack |
S01.03 |
||
|
11:42 – 12:06 |
In it for the Long Run: Calibrating Community Engagement Efforts to Local Contexts and New Challenges Alexandre Menezes |
S01.04 |
||
|
12:06 – 12:30 |
Funding and Sustaining Community Engagement Science – Partnerships, Politics and Power Steven Wakefield |
S01.05 |
||
| 10:30 – 12:30 |
Oral Abstract Session 07: |
Lotus 5 - 7, Level 22 |
||
| 10:30 - 10:45 |
Bispecific Fusion Antibodies PG9-Ibalizumab (PG9-iMab) and VRC01-Ibalizumab (VRC01-iMab) Exhibit 100% Breadth and Picomolar Potency CS Pace, R Song, D Franco, M Seaman, DD Ho |
OA07.01 |
||
|
10:45 - 11:00 |
Identification of Amino Acid Residues in HIV-1 Envelope Targeted by Plasma Broadly Neutralizing Antibodies using Evolutionary Models M Lacerda, PL Moore, N Ngandu, ES Gray, K Wibmer, M Nonyane, D Sheward, BT Korber, DC Montefiori, C Williamson, L Morris, C Seoighe |
OA07.02 |
||
|
11:00 - 11:15 |
Isolation of a Subset of Novel HIV-1 Broadly Neutralizing Antibodies with Dual Specificity Overlapping the Env Receptor and Coreceptor Binding Sites Slides Unavailable Y Li, S O'Dell, X Wu, S Schmidt, C Hogerkorp, Y Feng, B Chakrabarti, R Wilson, N Longo, N Doria-Rose, M Roederer, M Connors, R Wyatt, J Mascola |
OA07.03 |
||
|
11:15 - 11:30 |
Neutralizing Antibodies Inhibit HIV-1 Transfer from Dendritic Cells to Primary CD4 T Lymphocytes Slides Unavailable B Su, K Xu, M Peressin, A Lederle, S Schmidt, G Laumond, C Moog, V Holl |
OA07.04 |
||
|
11:30 - 11:45 |
Induction of Neutralizing Antibody Responses in HIV Infection Is Associated with HIV-Specific CD4 T Cell Responses Slides Unavailable M Mueller, M Lindqvist, D Soghoian, S Ranasinghe, T Wrin, P Phung, S Deeks, C Pilcher, F Hecht, H Streeck |
OA07.05 |
||
|
11:45 - 12:00 |
Influence of NK Cells and NK Cell Receptor Polymorphisms in the Assessment of HIV-1 Neutralization BK Brown, L Wieczorek, G Kijak, K Lombardi, J Currier, M Wesberry, C Ochsenbauer, JC Kappes, V Ngauy, M Marovich, N Michael, DC Montefiori, VR Polonis |
OA07.06 |
||
|
12:00 - 12:15 |
The Effect of HIV-1 Superinfection on the Development of Neutralizing Antibody Breadth Among Female Sex Workers in Mombasa, Kenya VC Cortez, J Overbaugh |
OA07.07 |
||
|
12:15 - 12:30 |
The Thai Phase III Clinical Trial (RV144) Induces the Generation of Antibodies That Target a Conserved Region Within the V2 Loop of GP120 N Karasavvas, E Billings, M Rao, J Currier, NL Michael, S Rerks-Ngarm, P Pitisuttithum, J Kaewkungwal, V Ngauy, S Nitayaphan, S Madnote, D Arworn, J Kim, M de Souza |
OA07.08 LB |
||
| 10:30 – 12:30 |
Oral Abstract Session 08: |
Lotus 5 - 7, Level 22 |
||
| 10:30 - 10:45 |
Evidence for CD4 T-Cell Mediated Immune Control of Macrophage Infection in Rhesus Macaques Undergoing CD4+ Lymphocyte Depletion Prior to SIV Infection A Ortiz, B Li, NR Klatt, B Lawson, E Ryzhova, P Carnathan, M Paiardini, J Else, F Gonzalez-Scarano, SJ Ratcliffe, J Brenchley, J Estes, C Derdeyn, G Silvestri |
OA08.01 |
||
|
10:45 - 11:00 |
CD4+ T Cell Escape in a SIVmac239-Infected Indian Rhesus Macaque Elite Controller with Breakthrough Viremia J Giraldo-Vela, FA Norante, AT Bean, EJ Leon, R Rudersdorf, NA Wilson, DI Watkins, JB Sacha |
OA08.02 |
||
|
11:00 - 11:15 |
Decreased Penetration of GFP-Labeled Lentiviral Particles in the Vagina and Endocervix of SIV∆3-Vaccinated Macaques Slides Unavailable A Carias, M Anderson, E Okocha, M McRaven, W Li, RP Johnson, T Hope |
OA08.03 |
||
|
11:15 - 11:30 |
Long-Term Programming of Antigen-Specific Immunity from Gene Expression Signatures in the PBMC of Rhesus Macaques Immunized with an SIV DNA Vaccine Slides Unavailable JD Boyer, SE Belisle, J Yin, DJ Shedlock, A Dai, J Yan, MG Lewis, H Andersen, JA Karl, DH O'Connor, A Khan, N Sardesai, RE Palermo, DB Weiner, MG Katze |
OA08.04 |
||
|
11:30 - 11:45 |
Compromised NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Chronic SIV Infection Slides Unavailable X He, Z Luo, M Jia, Y Li, Z Cong, D Li, H Liang, Y Shao |
OA08.05 |
||
|
11:45 - 12:00 |
Cytotoxicity Capacity of SIV-Specific CD8+ T Cells Against Primary Autologous Targets Correlates with Immune Control in SIV-Infected Rhesus Macaques D Mendoza, S Johnson, B Peterson, N Doria-Rose, G Franchini, D Schneider, MT Trivett, CM Trubey, V Coalter, DI Watkins, JD Lifson, SA Migueles, M Connors |
OA08.06 |
||
|
12:00 - 12:15 |
Live Attenuated Influenza-SIV Vaccines: Efficacy Against Mucosal Challenge in Macaques Slides Unavailable SJ Kent, S Jegaskanda, J Reece, T Ameresena, A Sexton, C Fernandez, J Stambas, A Brooks, R De Rose |
OA08.07 |
||
|
12:15 - 12:30 |
Reduction of Founder Virus in Vaccinated Monkeys after Mucosal SIV Challenge. Slides Unavailable JB Whitney, M Rolland, M Lacerda, PT Hraber, A DeCamp, C Luedemann, SS Rao, JR Mascola, B Korber, G Nabel, P Gilbert, C Seoighe, NL Letvin |
OA08.08 LB |
||
|
15:00 – 16:00 |
Lunch Break Young and Early-Career Investigators Networking Lunch Lunch tables in Ballroom B have been reserved for young and early career investigators to network with senior researchers. A list of featured researchers is available at the registration desk. |
Ballroom B, Level 22 |
||
| 13:30 – 15:00 |
Oral Abstract Session 09: |
Ballroom A, Level 22 |
||
| 13:30 - 13:45 |
T-Cell Responses Induced by Immunization with Ad35-HIV-1 Vaccines Are Broad, Durable, Polyfunctional and Can Mediate Inhibition of HIV JH Cox, P Hayes, E Cormier, D Gill, J Kopycinski, A Spentzou, L Hachaambwa, C Bunce, E Sayeed, A Lombardo, W Komaroff, K Loughran, B Barin, L Dally, J Ackland, T Tarragona, M Keefer, J Excler, P Fast, J Gilmour |
OA09.01 |
||
|
13:45 - 14:00 |
ADCC Titers to HIV-Infected Cells Are Detectable in the Majority of Vaccine Recipients in the RV144 Trial MD Alpert, JD Harvey, WJ Neidermyer, Y Huang, D Morris, L Harris, H Gao, DC Montefiori, P Pitisuttithum, J Kaewkungwal, S Nitayaphan, S Rerks-Ngarm, NL Michael, JH Kim, DT Evans |
OA09.02 |
||
|
14:00 - 14:15 |
Polyfunctional CD4/CD8 HIV-Specific Cytokine Responses and Presence of Cytolytic Markers in Swedish Vaccinees Immunized with HIV-1 DNA and HIV-1 MVA Slides Unavailable K Godoy-Ramirez, C Nilsson, K Karlén, T Tecleab, M Marovich, B Hejdeman, B Wahren, E Sandström, G Biberfeld |
OA09.03 |
||
|
14:15 - 14:30 |
Surface Plasmon Resonance Analysis of Anti-gp120 V2-Specific IgG Antibodies Generated in the RV144 Thai Trial Slides Unavailable EA Billings, N Karasavvas, MS de Souza, J Currier, P Pitisuttithum, J Kaewkunwal, S Nitayaphan, PB Gilbert, GD Tomaras, SB Zolla-Pazner, BF Haynes, NL Michael, S Rerks-Ngarm, JH Kim, M Rao |
OA09.04 |
||
|
14:30 – 14:45 |
V2-Reactive Antibodies in RV144 Vaccinees' Plasma Slides Unavailable S Zolla-Pazner, T Cardozo, A deCamp, B Haynes, J Kim, X Kong, N Michael, S Rerks-Ngarm, C Williams |
OA09.05 |
||
|
14:45 - 15:00 |
PedVacc001:Safety and Immunogenicity of a Candidate HIV-1 Vaccine,MVA.HIVA, Administered to Healthy Gambian Infants Born to HIV-1/2-Uninfected Mothers MO Afolabi, J Ndure, J Mueller, V Thomas, M Shams-Rony, N Borthwick, A Bridgeman, A Black, M Reilly, W Jaoko, G John-Stewart, G Ambler, B Lohman-Payne, T Hanke, KL Flanagan |
OA09.06 |
||
| 13:30 – 15:00 |
Oral Abstract Session 10: |
Lotus 1 - 4, Level 22 |
||
| 13:30 - 13:45 |
Eliciting Broadly Neutralizing Antibodies Against HIV-1 Using a Novel Antigen Containing gp41 Membrane-Proximal External Region Slides Unavailable D Han, H Habte, Y Qin, K Takamoto, C Labranche, D Montefiori, M Cho |
OA10.01 |
||
|
13:45 - 14:00 |
Neutralizing Antibody Responses Induced with V3-Scaffold Protein Boosts Following Priming with gp120 DNA S Zolla-Pazner, X Kong, X Jiang, T Cardozo, A Nadas, S Cohen, M Totrov, MS Seaman, S Wang, S Lu |
OA10.02 |
||
|
14:00 - 14:15 |
Phase I "Proof of Principle": Immunization with Virosome-Gp41-Derived Antigen Induces Mucosal Antibodies with Antiviral Properties Slides Unavailable G Leroux-Roels, C Maes, F Clement, F van Engelenburg, M van den Dobbelsteen, R Zurbriggen, M Amacker, M Adler, M Spengler, J Detmers, F Anjuere, L Lopalco, D Tudor, A Drillet, M Bomsel, A Chalifour, S Fleury |
OA10.03 |
||
|
14:15 - 14:30 |
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 R Jalah, V Patel, V Kulkarni, A Valentin, C Alicea, M Rosati, A von Gegerfelt, NY Sardesai, J Bess, Jr., JD Lifson, B Keele, RR Amara, HL Robinson, VM Hirsch, Y Guan, D Venzon, DC Montefiori, BK Felber, GN Pavlakis |
OA10.04 |
||
|
14:30 - 14:45 |
Direct Antibody Access to the HIV-1 MPER Positively Correlates with Neutralization Sensitivity BK Chakrabarti, LM Walker, JF Guenaga, A Ghobbeh, P Poignard, DR Burton, RT Wyatt |
OA10.05 |
||
|
14:45 - 15:00 |
A DNA Prime/Protein Boost Vaccine Leads to Higher B-Cell Responses than a Vector Prime/Protein Boost or DNA Prime/Vector Boost Regimens Slides Unavailable N Frahm, DP Friedrich, P Walsh, S De Rosa, P Spearman, S Barnett, M Keefer, P Goepfert, H Robinson, B Graham, H Liao, G Tomaras, B Haynes, S Rerks-Ngarm, J Kim, MJ McElrath |
OA10.06 |
||
|
15:00 – 16:00 |
Poster Viewing with Coffee Break |
Ballroom B, Level 22 |
||
| 13:30 – 15:00 |
Oral Abstract Session 11: |
Lotus 5 - 7, Level 22 |
||
| 13:30 - 13:45 |
Microarray Analysis of Cervical Tissue Reveals a Transcriptional Imprint that Correlates with Protective Immunity in SIV-ΔNef-Vaccinated Animals AJ Smith, SW Wietgrefe, CS Reilly, L Duan, Q Li, M Zeng, AT Haase |
OA11.01 |
||
|
13:45 - 14:00 |
Gut Inflammation and Indoleamine Deoxygenase Inhibit IL-17 Production and Induce Cytotoxicity in RORγt+ NKp44+ Mucosal NK Cells During SIV Infection R Reeves, P Rajakumar, TI Evans, M Connole, J Gillis, Y Kuzmichev, R Johnson |
OA11.02 |
||
|
14:00 - 14:15 |
Targeting the Vaginal Mucosa with Human Papillomavirus Pseudovirion Vaccines Delivering SIV DNA Slides Unavailable SN Gordon, RC Kines, G Kutsyna, Ma, A Hryniewicz, BF Keele, JN Roberts, C Fenizia, Hidajat, N Cuburu, B Buck, ML Bernardo, M Robert-Guroff, J Miller, BS Graham, DR Lowy, T Schiller, G Franchini |
OA11.03 |
||
|
14:15 - 14:30 |
Durability and Phenotype of SIV-Specific Mucosal T Lymphocyte Responses Elicited by Recombinant Adenovirus Vectors in Rhesus Monkeys H Li, J Liu, A Carville, KG Mansfield, S Clark, D Lynch, DH Barouch |
OA11.04 |
||
|
14:30 - 14:45 |
Role of Genital Tract Inflammation and T Cell Activation in CD4 Depletion at the Female Genital Tract During HIV Infection L Liebenberg, H Jaspan, D Coetzee, A Williamson, J Passmore |
OA11.05 |
||
|
14:45 - 15:00 |
SIV attenuated vaccine-induced plasma cells and antibodies limit infection at the portal of entry and systemically following vaginal challenge Slides Unavailable M Zeng, L Duan, Q Li, A Smith, S Wietgrefe, Pj Southern, CS Reilly, S Pambuccian, L Shang, PJ Skinner, M Zupancic, M Piatak, Jr, D Waterman, K Reeves, JD Lifson, P Johnson, AT Haase |
OA11.06 LB |
||
|
15:00 – 16:00 |
Poster Viewing with Coffee Break |
Ballroom B, Level 22 |
||
| 16:00 – 18:00 |
Symposia 02: |
Ballroom A, Level 22 |
||
| 16:00 – 16:24 |
Mucosal Gp41 Antibodies-Mediated Protection from Vaginal SHIV Challenges Slides Unavailable Morgane Bomsel |
S02.01 |
||
|
16:24 – 16:48 |
What is a Protective Antibody Response? Robert Gallo |
S02.02 |
||
|
16:48 - 17:12 |
Efficacy of Non-Neutralizing Antibodies in NHP Slides Unavailable Robin Shattock |
S02.03 |
||
|
17:12 – 17:36 |
Developing Broadly Neutralizing Antibodies from Between the Gaps of the Quantized Humoral Immune Response Peter Kwong |
S02.04 |
||
|
17:36 – 18:00 |
Broad Neutralization Coverage of HIV by Highly Potent Antibodies Slides Unavailable Pascal Poignard |
S02.05 |
||
| 16:00 – 18:00 |
Symposia 03: |
Lotus 1 - 4, Level 22 |
||
| 16:00 – 16:24 |
The Role of the MHC in Adaptive Immunity Against HIV Mina John |
S03.01 |
||
|
16:24 – 16:48 |
Host Genetic Factors That Influence HIV-1 Control Danielle van Manen |
S03.02 |
||
|
16:48 - 17:12 |
Next Generation Sequencing in HIV Host Genetics Kevin Shianna |
S03.03 |
||
|
17:12 – 17:36 |
Antivial Activity of NK Cells in HIV-1 Infection Slides Unavailable Marcus Altfeld |
S03.04 |
||
|
17:36 – 18:00 |
TRIM5 Polymorphism and Experimental Models of HIV Infection and AIDS Welkin Johnson |
S03.05 |
||
| 16:00 – 18:00 |
Symposia 04: |
Lotus 5 - 7, Level 22 |
||
| 16:00 – 16:24 |
Passive Immunization to Prevent HIV Infection: Potential Applications and Challenges Slides Unavailable Barney Graham |
S04.01 |
||
|
16:24 – 16:48 |
Development of Ibalizumab and Improved Variants for Passive Immunization Against HIV David Ho |
S04.02 |
||
|
16:48 - 17:12 |
Challenges in the Design of Future Combination Prevention Trials Slides Unavailable Magdalena Sobieszczyk |
S04.03 |
||
|
17:12 – 17:36 |
Regulatory Considerations for the Approval of Novel HIV Vaccine Clinical Trial Designs in a Developing Country Gavin Steel Management Sciences for Health (MSH) |
S04.04 |
||
|
17:36 – 18:00 |
Challenges of Integrating Mucosal Immune Assessments Into HIV Vaccine Trials Aggrey Omu Anzala |
S04.05 |
||
| 17:30 – 19:00 |
Poster Session 02 and Reception |
Ballroom B Level 22 |
||
|
All posters ending in even numbers were presented during Poster Session 02. |
||||
|
Thursday, 15 September (back to top) |
| 08:30 – 10:30 |
Symposia 05: |
Ballroom A, Level 22 |
||
| 08:30 – 08:54 |
Systems Biology of Dengue Infection Slides Unavailable Marcin Kwissa |
S05.01 |
||
|
08:54 – 09:18 |
Whole Blood Transcriptional Monitoring of Acute HIV-1 Infection Reveals Differential Signatures of Host Immune Activation Jason Skinner |
S05.02 |
||
|
09:18 – 09:42 |
Functional Genomic Analysis of the Human Slides Unavailable William Haining |
S05.03 |
||
|
09:42 – 10:06 |
Correlates of Immune Protection: A System Biology Analysis of Vaccine and Natural Mediated Immune Protection Slides Unavailable Rafick-Pierre Sekaly |
S05.04 |
||
|
10:06 – 10:30 |
Systems Vaccinology: Using the Tools of Systems Biology to Enable Rational Vaccine Design Erica Andersen-Nissen |
S05.05 |
||
| 08:30 – 10:30 |
Symposia 06: |
Lotus 1 - 4, Level 22 |
||
| 08:30 – 08:54 |
Harnessing Antibody-Mucus Interactions to Prevent HIV Transmission Slides Unavailable Thomas Hope |
S06.01 |
||
|
08:54 – 09:18 |
a4ß7/CD4 T Cells are Key Targets in Mucosal Transmission of HIV Slides Unavailable James Arthos |
S06.02 |
||
|
09:18 – 09:42 |
Critical Role of Retinoic Acid and Gut-Tropic Lymphocytes in Intestinal Immune Responses
J. Rodrigo Mora |
S06.03 |
||
|
09:42 – 10:06 |
Defining the Spectrum of Vaccine Induced Humoral Responses Slides Unavailable Georgia Tomaras |
S06.04 |
||
|
10:06 – 10:30 |
Correlates of Protection Against SIVmac251 in Vaccinated Rhesus Monkeys Slides Unavailable Dan Barouch |
S06.05 |
||
| 08:30 – 10:30 |
Symposia 07 |
Lotus 5 - 7, Level 22 |
||
| 08:30 – 08:54 |
A Deeper Look At The Virus Populations Infecting Step Trial Volunteers Slides Unavailable James Mullins |
S07.01 |
||
|
08:54 – 09:18 |
Sequence Analysis of HIV-1 Breakthrough Infections in the RV144 Trial Slides Unavailable Morgane Rolland |
S07.02 |
||
|
09:18 – 09:42 |
Increased Multiple Variant Transmission in VAX003 Injection Drug Users Katharine Bar |
S07.03 |
||
|
09:42 – 10:06 |
Sieve analysis of RV144 Paul Edlefsen |
S07.04 |
||
|
10:06 – 10:30 |
Understanding HIV Transmission Utilizing Transmitted/Founder Viruses Brandon Keele |
S07.05 |
||
|
10:30 – 11:00 |
Tea and Coffee Break |
Ballroom B, Level 22 |
||
| 11:00 – 12:30 |
Plenary Session 03: |
Ballroom A, Level 22 |
||
| 11:00 – 11:30 |
Development of HIV-1 Neutralizing Antibody Vaccines: From Structure to Immunogen Design Jeffrey Boyington |
PL03.01 |
||
|
11:30 – 12:00 |
Current Status and Future Directions of Vector Based HIV Vaccines C. Richter King |
PL03.02 |
||
|
12:00 – 12:30 |
New Generation of Adjuvants for HIV Vaccines Slides Unavailable Steven Reed |
PL03.03 |
||
| 12:30 – 13:30 |
Closing Session |
Ballroom A, Level 22 |
||
|
12:30 – 12:45 |
Closing Remarks |
|||
|
12:45 – 13:00 |
AIDS Vaccine 2012 |
|||
